2026 Q1 -tulosraportti
36 päivää sitten
‧1 t 1 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 | - | - | ||
| 19 | - | - | ||
| 34 | - | - | ||
| 61 966 | - | - | ||
| 50 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 981 387 | 1 981 387 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 981 387 | 1 981 387 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·9 t sittenIt's been an incredibly long time this stock has been "cheap" in light of expectations for business development. A bit difficult to understand, but the market is the market. One has probably been genuinely frightened before. I don't have any better explanation for this. One should probably expect that sometime in summer/autumn, big things will happen. But of course, the stock carries a certain risk here with a development company. The product development looks finished. Now several approvals and business development going forward remain.- ·3 päivää sitten · MuokattuNews retrieved from AI: "Pancreatic Cancer Action Network (PanCAN) & Aignostics Partnership (June 9, 2026): Today, PanCAN announced a major partnership with AI-pathology company Aignostics. They will be applying advanced AI spatial profiling models to PanCAN's SPARK platform—one of the largest pancreatic cancer datasets in the world. While this does not involve Immunovia directly, industry analysts note that these types of deep-learning AI partnerships are rapidly accelerating the entire biomarker and liquid biopsy market, creating a strong tailwind for targeted early-detection blood tests like PancreaSure."
- ·3 päivää sittenWhy are only Avanza's pension insurance customers flagged regarding this 10 percent ownership and not also Nordnet's customers? Is it because Nordnet pension insurance customers have a different ownership percentage? That Immunovia highlighted this Avanza ownership in an announcement in May, that doesn't really provide any particular reassurance that anyone larger is involved at all if this is a forest of collected small customers.
·3 päivää sitten10% is the disclosure threshold and as you say, it's a multitude of retail investors, i.e., no major party involved (via Avanza at least). You can see larger individual owners here https://immunovia.com/home/investors/ownership-structure/ 
·2.6.Doctor on new cancer medicine: "First time we beat chemotherapy" A new drug can make people suffering from pancreatic cancer survive twice as long, according to a new study. TT/Ny Teknik·2.6.Go to homepage. Logo, Ny Teknik Log in Search Search... INNOVATION Archive image. Fredrik Sandberg/TT Doctor on new cancer medicine: "First time we knock out chemotherapy" A new drug can make people suffering from pancreatic cancer survive twice as long, according to a new study. TT/Ny Teknik Published 1 Jun 2026 at 13.01 Last updated 2 Jun 2026 at 08.39 Advertisement In the study, on 500 patients in the USA with metastatic cancer, survival doubled from just over half a year to over 13 months compared to patients who instead received chemotherapy, reports Dagens Medicin. – "I am happy about this. The survival benefit is very large considering how difficult to treat this disease is," says Daniel Öhlund, oncologist and chief physician at Norrlands University Hospital in Umeå, to the newspaper. – "It is also the first time we get a drug that is more effective than cytostatics for broad patient groups." The drug, daraoxanrasib, inhibits a protein that is driving tumor development in most cases.·2.6.It would have been a dream if they could also get something that helps them out of the death sentence. Maybe it "buys them a little time so they can manage to make some new bold moves"?- ·1.6.Today's trading. Remember that we have to go all the way back to October 2025 to reach the previous issue. Those who have had cold feet should have disappeared (sold out at a loss) a long time ago. At 09:08 one sees a gap between sellers' price level in øre 19.92 and 20 and 20.05 up to 20.8. They have been doing this for months to trigger stop-loss. As soon as someone buys slightly larger blocks again, they withdraw and then re-evaluate the next level. This is robot trading (manipulation). One day when news is released, they will not be able to defend these heavy bluff sales of theirs. I believe in a GAP-up one day in the future. Of course impossible to predict exactly when. That is what I believe about the trading in this stock.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
36 päivää sitten
‧1 t 1 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·9 t sittenIt's been an incredibly long time this stock has been "cheap" in light of expectations for business development. A bit difficult to understand, but the market is the market. One has probably been genuinely frightened before. I don't have any better explanation for this. One should probably expect that sometime in summer/autumn, big things will happen. But of course, the stock carries a certain risk here with a development company. The product development looks finished. Now several approvals and business development going forward remain.
- ·3 päivää sitten · MuokattuNews retrieved from AI: "Pancreatic Cancer Action Network (PanCAN) & Aignostics Partnership (June 9, 2026): Today, PanCAN announced a major partnership with AI-pathology company Aignostics. They will be applying advanced AI spatial profiling models to PanCAN's SPARK platform—one of the largest pancreatic cancer datasets in the world. While this does not involve Immunovia directly, industry analysts note that these types of deep-learning AI partnerships are rapidly accelerating the entire biomarker and liquid biopsy market, creating a strong tailwind for targeted early-detection blood tests like PancreaSure."
- ·3 päivää sittenWhy are only Avanza's pension insurance customers flagged regarding this 10 percent ownership and not also Nordnet's customers? Is it because Nordnet pension insurance customers have a different ownership percentage? That Immunovia highlighted this Avanza ownership in an announcement in May, that doesn't really provide any particular reassurance that anyone larger is involved at all if this is a forest of collected small customers.·3 päivää sitten10% is the disclosure threshold and as you say, it's a multitude of retail investors, i.e., no major party involved (via Avanza at least). You can see larger individual owners here https://immunovia.com/home/investors/ownership-structure/
- ·2.6.Doctor on new cancer medicine: "First time we beat chemotherapy" A new drug can make people suffering from pancreatic cancer survive twice as long, according to a new study. TT/Ny Teknik·2.6.Go to homepage. Logo, Ny Teknik Log in Search Search... INNOVATION Archive image. Fredrik Sandberg/TT Doctor on new cancer medicine: "First time we knock out chemotherapy" A new drug can make people suffering from pancreatic cancer survive twice as long, according to a new study. TT/Ny Teknik Published 1 Jun 2026 at 13.01 Last updated 2 Jun 2026 at 08.39 Advertisement In the study, on 500 patients in the USA with metastatic cancer, survival doubled from just over half a year to over 13 months compared to patients who instead received chemotherapy, reports Dagens Medicin. – "I am happy about this. The survival benefit is very large considering how difficult to treat this disease is," says Daniel Öhlund, oncologist and chief physician at Norrlands University Hospital in Umeå, to the newspaper. – "It is also the first time we get a drug that is more effective than cytostatics for broad patient groups." The drug, daraoxanrasib, inhibits a protein that is driving tumor development in most cases.·2.6.It would have been a dream if they could also get something that helps them out of the death sentence. Maybe it "buys them a little time so they can manage to make some new bold moves"?
- ·1.6.Today's trading. Remember that we have to go all the way back to October 2025 to reach the previous issue. Those who have had cold feet should have disappeared (sold out at a loss) a long time ago. At 09:08 one sees a gap between sellers' price level in øre 19.92 and 20 and 20.05 up to 20.8. They have been doing this for months to trigger stop-loss. As soon as someone buys slightly larger blocks again, they withdraw and then re-evaluate the next level. This is robot trading (manipulation). One day when news is released, they will not be able to defend these heavy bluff sales of theirs. I believe in a GAP-up one day in the future. Of course impossible to predict exactly when. That is what I believe about the trading in this stock.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 | - | - | ||
| 19 | - | - | ||
| 34 | - | - | ||
| 61 966 | - | - | ||
| 50 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 981 387 | 1 981 387 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 981 387 | 1 981 387 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
2026 Q1 -tulosraportti
36 päivää sitten
‧1 t 1 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·9 t sittenIt's been an incredibly long time this stock has been "cheap" in light of expectations for business development. A bit difficult to understand, but the market is the market. One has probably been genuinely frightened before. I don't have any better explanation for this. One should probably expect that sometime in summer/autumn, big things will happen. But of course, the stock carries a certain risk here with a development company. The product development looks finished. Now several approvals and business development going forward remain.
- ·3 päivää sitten · MuokattuNews retrieved from AI: "Pancreatic Cancer Action Network (PanCAN) & Aignostics Partnership (June 9, 2026): Today, PanCAN announced a major partnership with AI-pathology company Aignostics. They will be applying advanced AI spatial profiling models to PanCAN's SPARK platform—one of the largest pancreatic cancer datasets in the world. While this does not involve Immunovia directly, industry analysts note that these types of deep-learning AI partnerships are rapidly accelerating the entire biomarker and liquid biopsy market, creating a strong tailwind for targeted early-detection blood tests like PancreaSure."
- ·3 päivää sittenWhy are only Avanza's pension insurance customers flagged regarding this 10 percent ownership and not also Nordnet's customers? Is it because Nordnet pension insurance customers have a different ownership percentage? That Immunovia highlighted this Avanza ownership in an announcement in May, that doesn't really provide any particular reassurance that anyone larger is involved at all if this is a forest of collected small customers.·3 päivää sitten10% is the disclosure threshold and as you say, it's a multitude of retail investors, i.e., no major party involved (via Avanza at least). You can see larger individual owners here https://immunovia.com/home/investors/ownership-structure/
- ·2.6.Doctor on new cancer medicine: "First time we beat chemotherapy" A new drug can make people suffering from pancreatic cancer survive twice as long, according to a new study. TT/Ny Teknik·2.6.Go to homepage. Logo, Ny Teknik Log in Search Search... INNOVATION Archive image. Fredrik Sandberg/TT Doctor on new cancer medicine: "First time we knock out chemotherapy" A new drug can make people suffering from pancreatic cancer survive twice as long, according to a new study. TT/Ny Teknik Published 1 Jun 2026 at 13.01 Last updated 2 Jun 2026 at 08.39 Advertisement In the study, on 500 patients in the USA with metastatic cancer, survival doubled from just over half a year to over 13 months compared to patients who instead received chemotherapy, reports Dagens Medicin. – "I am happy about this. The survival benefit is very large considering how difficult to treat this disease is," says Daniel Öhlund, oncologist and chief physician at Norrlands University Hospital in Umeå, to the newspaper. – "It is also the first time we get a drug that is more effective than cytostatics for broad patient groups." The drug, daraoxanrasib, inhibits a protein that is driving tumor development in most cases.·2.6.It would have been a dream if they could also get something that helps them out of the death sentence. Maybe it "buys them a little time so they can manage to make some new bold moves"?
- ·1.6.Today's trading. Remember that we have to go all the way back to October 2025 to reach the previous issue. Those who have had cold feet should have disappeared (sold out at a loss) a long time ago. At 09:08 one sees a gap between sellers' price level in øre 19.92 and 20 and 20.05 up to 20.8. They have been doing this for months to trigger stop-loss. As soon as someone buys slightly larger blocks again, they withdraw and then re-evaluate the next level. This is robot trading (manipulation). One day when news is released, they will not be able to defend these heavy bluff sales of theirs. I believe in a GAP-up one day in the future. Of course impossible to predict exactly when. That is what I believe about the trading in this stock.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 | - | - | ||
| 19 | - | - | ||
| 34 | - | - | ||
| 61 966 | - | - | ||
| 50 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 981 387 | 1 981 387 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 981 387 | 1 981 387 | 0 | 0 |